Key result
The R672S mutation in the SCN4A gene caused a hyperpolarizing shift in steady-state fast inactivation and enhanced slow inactivation, explaining hypokalemic periodic paralysis and acetazolamide worsening.
The R672S mutation in the SCN4A gene alters sodium channel inactivation, providing a potential mechanism for hypokalemic periodic paralysis and its exacerbation by acetazolamide.
Answers are grounded in this paper and cite their sources.
May guide genetic testing in hypokalemic periodic paralysis families; leaves open therapeutic translation pending larger validation studies.
A novel mutation in a family with hypokalemic periodic paralysis is described. The mutation R672S is located in the voltage sensor segment S4 of domain II in the SCN4A gene encoding the human skeletal muscle voltage-gated sodium channel. Functional expression of the R672S channels in human embryonic kidney 293 cells revealed a small but significant hyperpolarizing shift in the steady-state fast inactivation, and a dramatic enhancement in channel slow inactivation. These two defects are mainly due to a slow recovery of the mutant channels from fast and/or slow inactivation. Our data may help explain the mechanism underlying hypokalemic periodic paralysis and the patient's worsening from acetazolamide.
No takes yet. Share an insight, caveat, or question.
Bendahhou et al. (2001) studied Hypokalemic periodic paralysis. R672S mutation in SCN4A gene was evaluated on Channel inactivation defects (steady-state fast inactivation and slow inactivation). The R672S mutation in the SCN4A gene caused a hyperpolarizing shift in steady-state fast inactivation and enhanced slow inactivation, explaining hypokalemic periodic paralysis and acetazolamide worsening.
Synapse has enriched 10 related papers. Consider them for comparative context: